|
BCN1130 |
trans-Hinokiresinol
|
|
1. Hinokiresinol (trans-hinokiresinol) and nyasol (cis-hinokiresinol) possess appreciable estrogen receptor binding activity, they can stimulate the proliferation of estrogen-
dependent T47D breast cancer cells, and their stimulatory effects could be blocked by an estrogen antagonist, indicating that they are estrogen agonists.
2. trans- and cis-Hinokiresinols have similar free radical scavenging and anti-inflammatory activities, they also have anti-ischemic effects, only trans-hinokiresinol can significantly decrease neuronal injury in cultured cortical neurons exposed to oxygen-glucose deprivation followed by re-oxygenation.
3. Hinokiresinol is a novel inhibitor of LTB4 binding to the human neutrophils.
4. Hinokiresinol has antiallergic effect, it inhibits IgE-induced mouse passive cutaneous anaphylaxis reaction. |
|
BCN1136 |
Myricitrin
|
|
Myricitrin exhibits hepatoprotective, anti-inflammatory,antioxidant, anti-allergic, antinociception, anxiolytic-like, and antipsychotic-like effects. Myricitrin can be used as a drug candidate for the treatment of cardiovascular diseases, by effectively protecting cells from ox-LDL-induced endothelial cell apoptosis and reducing atherosclerotic plaque formation. Myricitrin is also a nitric oxide (NO) and protein kinase C (PKC) inhibitor that has central nervous system activity. |
|
BCN1140 |
Phytolaccagenin
|
|
Phytolaccagenin has promising antifungal activity against ATCC standard cultures of Candida albicans and Cryptococcus neoformans, and against clinical isolates of these fungi, it also shows inhibitory effects on lipopolysaccharide-induced NO production, and haemolytic activities. |
|
BCN1142 |
5-Hydroxy-4-methoxycanthin-6-one
|
|
1. 5-Hydroxy-4-methoxycanthin-6-one exhibits significant cytotoxic activity against CNE2 cell line.
2. 4-Methoxy-5- hydroxycanthin-6-one has anti-inflammatory effect, it can significantly inhibit the production of NO and the release of TNF-α induced by LPS in macrophage RAW 264.7.
3. After oral administration, 4-methoxy-5- hydroxycanthin-6-one (3, 9, and 27 mg/kg) can reduce the development of carrageenan-induced paw edema and complete Freund's adjuvant (CFA)-induced chronic arthritis in rats.
4. 4-Methoxy-5-hydroxycanthin-6-one has protective effect on dextran sulfate sodium
-induced rat colitis. |
|
BCN1147 |
3,4-O-Isopropylidene shikimic acid
|
|
1. 3,4-Oxo- isopropylidene-shikimic acid has significant anti-inflammatory effect which may be related to inhibiting the production of prostaglandin E2 and protecting free radical against oxidation.
2. 3,4-Oxo-isopropylidene-shikimic acid has protective effects on experimental colitis induced by trinitrobenzenesulfonic acid in rats, probably due to an antioxidant action.
3. 3,4-Oxo-isopropylidene-shikimic acid has anti-thrombosis effect, it inhibits thrombosis by anti-platelet-aggregation.
4. 3,4-Oxo-isopropylidene shikimic acid relieves the brain edema of rats subjected to MCAT by improving the energy metabolism and Na +, K +-ATPase activity in rat brain tissue.
5. 3,4-Oxo-isopropylidene-shikimic acid can inhibit adhesion of polymorphonuclear leukocyte to TNF-alpha-induced endothelial cells in vitro.
6. 3,4-Oxo-isopropylidene-shikimic acid has analgesic and antioxidant activities, it exhibits moderate antioxidant activity by scavenging the superoxide radical and hydroxyl radical with IC50 values of 0.214 and 0.450 ug/mL, respectively.
7. 3,4-Oxo-isopropylidene-shikimic acid has exhibited ameliorative effect on cognitive impairment in experimental animal models of dementia, it can promote adipogenesis by up-regulating expressions of C/EBP β, PPAR γ, C/EBP α, aP2 and FAS, and also stimulate adipokines during adipocyte differentiation, suggests that stimulation of adipokines and cognitive enhancing effect of 3,4-oxo-isopropylidene-shikimic acid have some relationship. |
